South Korea-based AI-powered genomic diagnostics company 3billion has launched 3B-NEO, an advanced genomic newborn screening (gNBS) service designed to identify genetic risks in newborns before symptoms appear, enabling earlier medical intervention and improved health outcomes.
The company said the service was developed in response to increasing global demand for genomic newborn screening from healthcare providers and international partners, as the field continues to gain traction worldwide.
Changwon Keum, CEO of 3billion, said, “Genomic newborn screening creates the greatest value when it enables action before symptoms appear.”
“Advances in genomic medicine are making it increasingly possible to identify health risks early and prepare appropriate medical interventions before irreversible complications develop. Through 3B-NEO, we aim to help healthcare providers and families make earlier, more informed decisions that can improve long-term health outcomes,” Keum added.
According to the company, unlike traditional newborn screening programmes, which mainly rely on biochemical markers and assess a limited number of conditions, 3B-NEO analyzes 595 carefully selected genes linked to serious childhood-onset disorders where early treatment, monitoring, or medical management may significantly improve outcomes.
The gene panel include inherited metabolic disorders, immunologic disorders, neuromuscular diseases, cardiovascular conditions, and other clinically significant pediatric genetic disorders.
3B-NEO is available in two testing options: a Whole Exome Sequencing (WES)-based standard test and a Whole Genome Sequencing (WGS)-based premium test. Test results are typically delivered within two weeks after sample receipt.
Healthcare providers can offer 3B-NEO without establishing in-house genomic testing infrastructure, while parents can request testing through participating healthcare providers following clinical review and approval.
3billion noted that genomic newborn screening is gaining clinical validation through large-scale research initiatives and pilot programmes across the United States, Europe, and other regions, driving demand for earlier genetic risk assessment.
The launch of 3B-NEO marks a significant expansion of 3billion’s precision medicine platform beyond rare disease diagnostics into proactive genomic healthcare across the life cycle.
Founded in 2016, 3billion provides AI-powered genomic interpretation and rare disease diagnostic services to healthcare professionals in more than 75 countries and over 800 partner institutions globally.
As part of its expansion strategy in the United States, the company has established a US subsidiary in Austin, Texas, and is preparing local laboratory operations to strengthen support for healthcare providers and patients across the country.
